Prospectively, all new therapeutic strategies aimed to potentiate adiponectin actions (i.e., increasing its circulating levels or the binding to its own receptor) should be carefully assessed separately in ERα-positive and ERα-negative breast cancers. Here, ESR1 is linked to breast carcinoma.